Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...

Flying a thrust-vectoring rocket can be a challenge, and even more so if you stack multiple stages and a minimalist flight computer on top of it all. But [Joe Barnard] is not one to shy away from ...

For all its simplicity, the arcade classic Asteroids was engaging in the extreme, with the ping of the laser, the rumble of the rocket ... part of Asteroids was the vector display.

Rocket Pharmaceuticals ... Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based ...

RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...

Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and ...